Cantel Medical Corp. (NYSE:CMN) Chairman Charles M. Diker sold 7,000 shares of the business’s stock in a transaction on Wednesday, October 19th. The stock was sold at an average price of $76.33, for a total value of $534,310.00. Following the transaction, the chairman now directly owns 3,174,975 shares of the company’s stock, valued at approximately $242,345,841.75. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Shares of Cantel Medical Corp. (NYSE:CMN) traded down 0.50% during trading on Wednesday, reaching $75.73. The company’s stock had a trading volume of 71,058 shares. The stock’s 50-day moving average is $78.00 and its 200-day moving average is $71.33. The stock has a market cap of $3.13 billion, a P/E ratio of 52.66 and a beta of 1.59. Cantel Medical Corp. has a 12-month low of $55.01 and a 12-month high of $81.63.
Cantel Medical Corp. (NYSE:CMN) last released its earnings results on Thursday, September 29th. The company reported $0.48 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.37 by $0.11. Cantel Medical Corp. had a return on equity of 16.70% and a net margin of 9.02%. The business earned $179 million during the quarter. During the same period in the prior year, the business earned $0.39 earnings per share. The business’s quarterly revenue was up 18.3% compared to the same quarter last year. Equities research analysts anticipate that Cantel Medical Corp. will post $1.98 earnings per share for the current fiscal year.
The company also recently announced a semiannual dividend, which will be paid on Tuesday, January 31st. Shareholders of record on Tuesday, January 17th will be given a $0.07 dividend. This is an increase from Cantel Medical Corp.’s previous semiannual dividend of $0.06. This represents a yield of 0.18%. The ex-dividend date of this dividend is Thursday, January 12th. Cantel Medical Corp.’s dividend payout ratio (DPR) is currently 8.33%.
A number of research firms have recently commented on CMN. Benchmark Co. set a $83.00 price target on Cantel Medical Corp. and gave the stock a “buy” rating in a report on Saturday, October 1st. Needham & Company LLC began coverage on Cantel Medical Corp. in a report on Wednesday, August 24th. They set a “hold” rating for the company.
A number of hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its position in Cantel Medical Corp. by 4.8% in the first quarter. Geode Capital Management LLC now owns 310,022 shares of the company’s stock worth $22,123,000 after buying an additional 14,211 shares during the last quarter. Kimelman & Baird LLC raised its position in Cantel Medical Corp. by 1.8% in the first quarter. Kimelman & Baird LLC now owns 399,811 shares of the company’s stock worth $28,531,000 after buying an additional 7,074 shares during the last quarter. Quadrature Capital Ltd bought a new position in Cantel Medical Corp. during the first quarter worth approximately $232,000. UBS Group AG raised its position in Cantel Medical Corp. by 2.6% in the first quarter. UBS Group AG now owns 52,630 shares of the company’s stock worth $3,756,000 after buying an additional 1,348 shares during the last quarter. Finally, State Street Corp raised its stake in Cantel Medical Corp. by 1.4% in the first quarter. State Street Corp now owns 698,437 shares of the company’s stock valued at $49,838,000 after buying an additional 9,417 shares in the last quarter. 81.61% of the stock is owned by institutional investors and hedge funds.
Cantel Medical Corp. Company Profile
Cantel Medical Corp. is a provider of infection prevention and control products and services in the healthcare market. The Company’s segments include Endoscopy, Water Purification and Filtration, Healthcare Disposables, Dialysis and Specialty Packaging. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.
Receive News & Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related companies with MarketBeat.com's FREE daily email newsletter.